Patience for patients: Ensuring the future of biotech

In the past ten years, biotech (or techbio, depending on who you ask), has made ungodly progress. From CGT to bioinformatics, we're entering a world that makes the sci-fi of the last century look timid. But there is a barrier to enter this new world. Cost. The prolonged timelines inherent in biotech, from research to approval processes, and the uncertainty around a viable product existing at the end of these cycles, are uncomfortable territory for many. That healthcare needs biotech to work is almost without question. Patients and clinicians alike are longing for new treatments - how can biotech ensure not to lose their patience?